Cargando…

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies

BACKGROUND: Compliance to disease modifying therapy (DMT) is associated with a reduced risk of relapse, lower healthcare resource utilization, and improved health-related quality of life in patients with multiple sclerosis (MS). Our objective was to assess the compliance and discontinuation rates of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duquette, Pierre, Yeung, Michael, Mouallif, Soukaïna, Nakhaipour, Hamid Reza, Haddad, Paola, Schecter, Robyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331106/ https://www.ncbi.nlm.nih.gov/pubmed/30640935 http://dx.doi.org/10.1371/journal.pone.0210417

Ejemplares similares

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches
por: Grand′Maison, Francois, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

The role of exercise in modifying outcomes for people with multiple sclerosis: a randomized trial
por: Mayo, Nancy E, et al.
Publicado: (2013)

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations
por: Arnold, Douglas L, et al.
Publicado: (2015)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Chinese and white Canadian satisfaction and compliance with physicians
por: Liu, Richard, et al.
Publicado: (2007)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study
por: Georgakopoulos, Jorge R., et al.
Publicado: (2020)

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
por: Melesse, Dessalegn Y, et al.
Publicado: (2017)

Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia
por: Shadi, Zari
Publicado: (2023)

Clinical insights on the spasticity-plus syndrome in multiple sclerosis
por: Alami Marrouni, Kanza, et al.
Publicado: (2022)

Impairment, disability and fatigue in multiple sclerosis
por: Shahrbanian, Shahnaz, et al.
Publicado: (2018)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE
por: Donzé, Cécile, et al.
Publicado: (2015)

The Phenotypic Spectrum of Tuberous Sclerosis Complex: A Canadian Cohort
por: Alsowat, Daad, et al.
Publicado: (2021)

Impact of an Education Program for Caregivers of Patients with Alzheimer's Disease on Treatment Discontinuation and Compliance in Korea
por: Kim, Hee-Jin, et al.
Publicado: (2021)

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

The Canadian Natural Health Products (NHP) Regulations: Industry Compliance Motivations
por: Laeeque, Hina, et al.
Publicado: (2007)

Inequalities in availability and compliance of school food programs in Canadian elementary schools
por: Maximova, K, et al.
Publicado: (2023)

Examining the Nutritional Quality of Canadian Packaged Foods and Beverages with and without Nutrition Claims
por: Franco-Arellano, Beatriz, et al.
Publicado: (2018)

Nutrition Claims Frequency and Compliance in a Food Sample of the Spanish Market: The BADALI Study
por: Ropero, Ana B., et al.
Publicado: (2020)

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
por: Agashivala, Neetu, et al.
Publicado: (2013)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder
por: Wada, Naoki, et al.
Publicado: (2022)

Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults
por: LaMori, Joyce, et al.
Publicado: (2022)

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
por: Nicholas, Jacqueline, et al.
Publicado: (2017)

Walking with UAN.GO Exoskeleton: Training and Compliance in a Multiple Sclerosis Patient
por: Sesenna, Gianluca, et al.
Publicado: (2021)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Mining rich health data from Canadian physician claims: features and face validity
por: Cunningham, Ceara Tess, et al.
Publicado: (2014)

The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors
por: Laeeque, Hina, et al.
Publicado: (2006)

Retrospective cohort study of compliance with post-deployment screening in the Canadian Armed Forces
por: Beliveau, Peter J H, et al.
Publicado: (2019)

Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients
por: Boucher, Annie, et al.
Publicado: (2007)

Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva(®)) in Patients with Multiple Sclerosis: An Observational Retrospective Study
por: Abolfazli, Roya, et al.
Publicado: (2023)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
por: Caballero, Joshua, et al.
Publicado: (2023)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs
por: Munsell, Michael, et al.
Publicado: (2017)

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database
por: Boster, Aaron, et al.
Publicado: (2017)

Compliance with Pharmacotherapy and Direct Healthcare Costs in Patients with Parkinson’s Disease: A Retrospective Claims Database Analysis
por: Richy, Florent F., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a76ln72077hnvhfgnl6ilce2uu